A non-enzymatic, isothermal strand displacement and amplification assay for rapid detection of SARS-CoV-2 RNA

Mohsen Mohammadniaei1✉, Ming Zhang1, Jon Ashley1, Ulf Bech Christensen2, Lennart Jan Friis-Hansen3, Rasmus Gregersen4, Jan Gorm Lisby5, Thomas Lars Benfield6, Finn Erland Nielsen4, Jens Henning Rasmussen4,7, Ellen Bøtker Pedersen8, Anne Christine Rye Olinger8, Lærke Tørring Kolding8, Maryam Naseri1, Tao Zheng1, Wentao Wang1, Jan Gorodkin9 & Yi Sun1✉

The current nucleic acid signal amplification methods for SARS-CoV-2 RNA detection heavily rely on the functions of biological enzymes which imposes stringent transportation and storage conditions, high cost and global supply shortages. Here, a non-enzymatic whole genome detection method based on a simple isothermal signal amplification approach is developed for rapid detection of SARS-CoV-2 RNA and potentially any types of nucleic acids regardless of their size. The assay, termed non-enzymatic isothermal strand displacement and amplification (NISDA), is able to quantify 10 RNA copies µL−1. In 164 clinical oropharyngeal RNA samples, NISDA assay is 100 % specific, and it is 96.77% and 100% sensitive when setting up in the laboratory and hospital, respectively. The NISDA assay does not require RNA reverse-transcription step and is fast (<30 min), affordable, highly robust at room temperature (>1 month), isothermal (42 °C) and user-friendly, making it an excellent assay for broad-based testing.

1Department of Health Technology, Technical University of Denmark, Lyngby, Denmark. 2PentaBase A/S, Petersmindevej 1 A, Odense C, Denmark. 3Department of Clinical Biochemistry, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. 4Department of Emergency Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. 5Department of Clinical Microbiology 445, Copenhagen University Hospital - Amager and Hvidovre, Copenhagen, Denmark. 6Department of Infectious Diseases, Copenhagen University Hospital - Amager and Hvidovre, Hvidovre, Denmark. 7Center for Translational Research, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. 8Department of Occupational and Environmental Medicine, Copenhagen University Hospital - Bispebjerg and Frederiksberg, Copenhagen, Denmark. 9Center for non-coding RNA in Technology and Health, Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C, Denmark. ✉email: mohmo@dtu.dk; suyi@dtu.dk
The outbreak of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) has imposed a huge burden on healthcare systems worldwide. As the pandemic is far from contained, there are critical needs to escalate testing, isolation, and contact tracing efforts. Large-scale testing allows health services to quickly identify the positive cases and arrange for them to receive the care needed. Isolating known cases prevents them from coming into contact with others and slows down the transmission rate. Testing all suspected cases is also a vital part to understand how prevalent the disease is and how it is evolving. However, the critical shortcoming of the laboratory-based test is the need for special training of the laboratory workers and the usage of complex readout instruments. The long process often causes delayed decision on quarantine or hospitalizations. Further, testing in remote areas is, among others, restricted by the lack of established funding support and limited numbers of cool storage systems to protect the degradation of reagents. Therefore, there is a great need to develop a simple, robust, fast, affordable, and ultra-sensitive assay/kit for the detection of SARS-CoV-2. To prepare for future outbreaks, it is preferred that the method can also be able to perform on any type/size of nucleic acids.

To keep up with the high transmission rate of the COVID-19, SARS-CoV-2 tests have been developed at a record-breaking pace, and in the vitro diagnostic (IVD) market experienced an unprecedented dynamic. Nucleic acid-based diagnostics, that screens naso/oropharyngeal swab samples for viral RNA, are commonly used to identify those who have an active coronavirus infection. Although chest computed tomography (CT) and serology tests are being used for COVID-19 diagnosis, the gold standard for SARS-CoV-2 RNA detection is still quantitative reverse transcription-polymerase chain reaction (qRT-PCR). During the process, the target RNA is initially transcribed into complementary DNA (cDNA) by reverse transcriptase, and then the cDNA is amplified exponentially with the help of a Taq polymerase. The qRT-PCR is very powerful due to its high sensitivity and specificity and the method has been widely established in many countries, playing key roles in controlling the pandemic. However, qRT-PCR requires a dedicated machine to accurately cycle through different temperatures, and the whole reaction can take up to 3 h. To enable a simpler and faster diagnosis of SARS-CoV-2, many companies and institutes are striving to develop isothermal amplification methods. Abbott’s ID NOW COVID-19 test utilizes a nicking endonuclease isothermal amplification reaction (NEAR) to rapidly generate short amplicons, which can be integrated into portable point-of-care (POC) devices. During the process, the target-recognition elements.

The sensing strategy also provides a universal platform for the detection of other genes (RNA or DNA) by simply substituting the target-recognition elements. Due to the biological origins, these molecular tools are not efficient for long DNA/RNA targets (whole genomes) and they typically use enzymatic steps to produce short cDNAs for subsequent signal amplifications.

Here, we show a one-pot, enzyme-free, isothermal assay that can rapidly detect SARS-CoV-2 RNA in clinical samples, termed nonenzymatic isothermal strand displacement and amplification (NISDA) assay. Compared to TMSD, the NISDA mechanism comprises two parts: “displacement” and “amplification” (Fig. 1). In the displacement step, the long viral RNA is exchanged into a short DNA template using a DNA duplex (Initiator) containing an overhang toehold with enhanced binding affinity using intercalating nucleic acid (INA) technology. The amplification step, the resulting DNA template initiates the cascade unfolding of two DNA molecular beacon structures (probes M1 and M2), leading to a dramatic enhancement in the fluorescence intensity of probe M1. In contrast to the previous target recycling TMSD assays, the presence of the toehold domain of the probe M1 at its loop region (c domain) enables proper and facile fluorophore/quencher labeling at both ends. NISDA assay is able to detect SARS-CoV-2 RNA in 30 min at 42 °C with a limit of detection (LoD) of five RNA copies µL⁻¹ diluted in water and ten RNA copies µL⁻¹ spiked in validated CoV-19-negative oropharyngeal RNA extract matrix. The assay is clinically validated on 127 oropharyngeal RNA extract specimens (65 negative and 62 positive with diverse Ct values) in the laboratory, and on 37 randomized clinical samples at the hospital. NISDA assay represents 100% specificity and it is 96.77% sensitive when operating in the laboratory and 100% sensitive on-site at the hospital.

Results

NISDA assay mechanism. As shown in Fig. 1, the key components of the assay include an Initiator and two probes (M1 and M2). The Initiator is a dsDNA composed of an INA strand with a toehold sequence which is partially complementary to the Template DNA, and completely complementary to the viral RNA. The probe M1 is labeled with 6-carboxyfluorescein (FAM) and bhq_1 quencher at the end of the stem. In the absence of the viral duplex. The kinetics of strand displacement is modulated by the toehold—the short single-stranded DNA segment overhanging on the original duplex. The process is nonenzymatic and controlled by the Gibbs free energy of hybridization and toehold exchange. The principle has been applied to detect nucleic acid targets, such as miRNAs or gene segments with the length of 19–23 nt. By rational design, the presence of the target strand can trigger multiple downstream cascade reactions. However, to enhance the sensitivity of the TMSD method, target recycling mechanisms such as hybridization chain reaction, programmable self-assembly method, and catalytic hairpin assembly have been developed and applied in DNA biosensing. Wherein, the target nucleic acid initiates a cascade reaction, then the target is recycled (not wasted) and reused for further reactions. Nevertheless, in these methods due to the location of toehold overhang at the end of the hairpin stem region, internal fluorophore/quencher labeling is required, which imposes more cost and improper quenching of the fluorophore following by high background signals. More importantly, these molecular tools are not efficient for long DNA/RNA targets (whole genomes) and they typically use enzymatic steps to produce short cDNAs for subsequent signal amplifications.

Recently, toehold-mediated strand displacement (TMSD) has emerged as an alternative cost-effective isothermal amplification technique. TMSD is based on competitive hybridization reactions, where an incoming nucleic acid strand outcompetes the other strand from a DNA or RNA duplex to form a better-matched
RNA, the spontaneous interactions between the Initiator and probes are kinetically blocked, and there is no fluorescence signal as the fluorophore and quencher are in close vicinity.

The workflow of the NISDA assay is as following. First, the total RNA is extracted from oropharyngeal swab samples collected from patients (Clinical isolation, Hvidovre Hospital, Denmark), then added to the reaction mixture following by incubation at 42°C for 30 min and fluorescence measurement. When the target viral RNA is present (Fig. 1), it is recognized by the Initiator through the toehold sequence of the INA strand. The INA then starts to hybridize with the viral RNA, leading to the Template displacement. This step, termed “displacement”, is the process of exchanging a long viral RNA to a short DNA template. This step is critical, as the subsequent signal amplification is much more efficient with the short template.

Driven by the entropy, the released Template then hybridizes with the molecular beacon structure of probe M1 (Fig. 1). The hairpin structure of probe M1 is opened, and the b’ sequence is accessible to function as a toehold-binding site for the subsequent hybridization with the b sequence of probe M2. Due to the strand-displacement process, probe M2 displaces the initial Template by hybridization with probe M1 to form a more stable duplex structure. Afterward, the displaced Template acts as a fuel to open another probe M1 hairpin and initiate a new hybridization cycle. The process is termed “amplification”. Unfolding the probe M1 results in a distinct change in the fluorescence intensity arising from FAM, as the fluorophore and quencher are brought further apart. After 30 min of reaction at 42°C, more M1:M2 pairs are formed, and the fluorescence intensity of the solution increases significantly. Based on the intensity change, the positive and negative test results can be easily distinguished by an optical reader.

**Fig. 1 NISDA assay for rapid detection of SARS-CoV-2 RNA.** The reaction mixture contains three key components, including a DNA duplex (the Initiator), and two DNA molecular beacon structures (probe M1 and probe M2). In presence of viral RNA/DNA, toehold-mediated template displacement and cascade signal amplification occur sequentially, following by fluorescence detection after 30 min at 42°C. INA is intercalating nucleic acid with enhanced binding affinity. F and Q denote for 6-Fam fluorophore and bhq-1 quencher, respectively. Letter labels denote for domains. The domains labeled with primes are complementary sequences.

**Design of the molecular structures.** We selected two specific sequences of RNA-dependent RNA polymerase (RdRP) and nucleoprotein (N) genes, for the selective detection of SARS-CoV-2 with minimal cross-target affinity to other types of human coronaviruses (Supplementary Fig. 1). The sequences of the Initiator, and probe M1 and M2 are listed in (Supplementary Table 1). As mentioned above, the NISDA mechanism comprises two parts: “displacement” and “amplification”. At first, we had to make sure that the amplification part on a short Template sequence would work properly. Optimum 22 nt DNA sequence identical to the RdRP and N genes were chosen for the Template (Fig. 2 and Supplementary Table 1) and M1 and M2 were subsequently designed. The rational design of the M1 and M2 was a prerequisite to minimize their interaction in the absence of the Template. In our first design, the length of the Template was chosen to be 30 nt. As shown in the polyacrylamide gel electrophoresis (PAGE) analysis for N gene probes (Fig. 2a), given the lane V, it can be clearly seen that M1 and M2 did not interact/hybridize with each other before the Template addition. Lane IV shows that the M1 was easily opened and hybridized with Template, while the Template could not open the M2 in the absence of M1 (lane VI). However, after the addition of the Template in the mixture of M1 and M2, a new band was observed and no band was seen for the recycled Template (lane VII). We supposed that, the released Template from Template:M1 duplex might be hybridized with M2 to form Template:M1:M2 triplex, hence hampering the cascade reaction. Therefore, we speculated that reducing the length of the Template from its 3’-end (segment c’) would decrease its binding affinity to the leftover sequence of M2 at its 5’-end (segment c). Interestingly, decreasing the Template length to 28 nt and 26 nt resulted in the appearance of a new band under the Template:M1:M2 triplex (Supplementary Fig. 2a, b). However, still no band was observed for the recycled Template. A shorter Template of 24 nt (Supplementary Fig. 2c) resulted in the disappearance of the Template:M1:M2 triplex and having a more clear band at the lower position. Although, the efficiency was still low due to the existence of the Template:M1 band, illustrating that considerable amounts of the Templates are still engaged with M1 strands and cannot contribute in the cascade reaction. Decreasing the Template length to 22 nt led to a very proper result (Fig. 2b). Almost all of the M1 strands were consumed to successfully form M1:M2 duplex and the Template was effectively recycled. In order to ensure that the observed band at lane VII was exactly attributed to the M1:M2 duplex, we annealed M1 and M2 in the absence of Template and compared the result with the mixture of M1, M2, and Template. According to the gel data in Fig. 2b (right panel), the M1:M2 duplex was perfectly formed upon the Template addition. From the obtained data, the robustness of our design was evidential due to the fact that almost all of the M1 primers were consumed after the addition of Template (lane VIII), while there were still considerable amount of un-hybridized M1 after annealing with M2 (lane IX). Similar performance was observed for the RdRP gene probes (Supplementary Fig. 3).

For the displacement part, it was necessary to have a balanced design on the Initiator, composed of the Template and a DNA strand with enhanced affinity (INA). The critical issue was to design the INA to have (i) high binding affinity to efficiently and
specifically bind to the whole RNA genome, and (ii) sufficient stability to facilitate the strand displacement. Therefore, the best condition was to increase the affinity only at the toehold sequence of the complementary DNA. Although, one can use any other types of high-affinity nucleic acids such as peptide nucleic acids (PNA) and locked nucleic acid (LNA) as they have been widely used for performance enhancement of DNA biosensors27–29. The complementary DNA harboring different toehold lengths (8 and 15 nt) with and without the INA were synthesized by PentaBase A/S. PentaBase’s proprietary INA® technology is on the basis of insertion of a base unit (intercalator) that is intercalated into nucleobases without disrupting or substituting any nucleotide in the nucleic acid sequence. The integrated INA® increases the stacking of the duplex helix, which enhances the specificity and affinity of the oligonucleotide. Although, the numbers, types, and positions of the intercalators need to be rationally designed such that a minimum degree of flexibility and a maximum duplex stability is achieved. According to the reported article26, the best conformation would be having three or four nucleotides distance between each two intercalators. Therefore, we decided to have the 8 nt and the 15 nt toehold sequences modified with two and four intercalators, respectively. However, the type and the positions of intercalators were calculated and optimized by PentaBase A/S to minimize secondary structures and achieve higher duplex stabilities. As clearly seen in Supplementary Fig. 4, compared to the natural DNA strands, the corresponding INA18 (harboring high-affinity 8 nt toehold sequence; t8 indicates the toehold length) and INA115 showed higher duplex stabilizations as determined by the raise in the melting temperatures (ΔTm (on average)) = + 3.2 °C for INA18, and + 8.7 °C for INA115).

To illustrate the displacement part using PAGE analysis, we used a mimic SARS-CoV-2 DNA sequence (85 nt) and mixed it with different purified Initiators. Figure 2c (right panel), demonstrates a typical PAGE analysis on the displacement of Template by mimic SARS-CoV-2 (85 nt) strand. T denotes for Template. All the molecular weight markers are 100 bp. Each experiment was repeated at least two times independently.
Fig. 3b and c, almost similar assay responses were observed for function of Initiator in the Template displacement reaction mixture (M1 and M2), in <20 min the both probe sets. After the addition of the Template into the signal saturation, as the assay could detect 300 nM in 10 min with the LoD of 133 aM and 181 aM, respectively (Fig. 3b, c).

Function of Initiator in the Template displacement. Before the final development of the NISDA assay for the whole genome, exchanging the RdRP and N genes of synthetic SARS-CoV-2 RNA (TWIST Bioscience) into the corresponding Templates were evaluated using different types of Initiators (denoted as T/nucleic acid^{x}x duplex; T stands for Template, x stands for the length of toehold sequence). Reaction mixtures composed of M1, M2, and three types of Initiators (T/DNA^{15}, T/INA^{1,8}, and T/INA^{1,15}) were prepared and incubated with SARS-CoV-2 RNA (10^{6} copies per µL) while the FAM fluorescence was recorded over time at 42 °C. As illustrated in Fig. 4, for both RdRP and N genes, upon the SARS-CoV-2 addition only the reaction mixtures containing T/INA^{1,15} showed fluorescence signal enhancement, whereas the other Initiators (T/DNA^{1,15} and T/INA^{1,8}) did not show any significant signals, meaning that the T/INA^{1,15} could capably function to exchange the whole genome to the corresponding Template and further signal amplification. This might be due to the fact that the longer toehold (15 nt) sequence provides more binding sites and higher stability hence greater specificity and binding efficiency to the target sequence at 42 °C. Although, INAs with longer toeholds (>15 nt) did not show good performances, possibly because of self-folding and dimer formations. Moreover, given the inefficiency of the unmodified T/DNA^{1,15}, increasing the affinity of the toehold sequence using INA technology was necessary for the assay to successfully undergo the strand displacement. This might be due to the unpredicted 3D structure and inherit self-folding (stem-loop formation) of the whole RNA genome to hamper a proper hybridization of DNA to its corresponding binding site. More importantly, compared to the RdRP gene, the NISDA assay on the N gene showed faster (~30 min) and more sensitive performance (dramatic signal enhancement).

To address why the NISDA assay functioned more efficiently for the N gene rather than the RdRP gene, we carried out an RNA structure analysis at 42 °C using RNAfold^{30}. By comparing the folded-binding sites, we observed that the RdRP binding site folded into a single hairpin with about twice as strong folding energy as the N-binding site which folded into two smaller stems.
Fig. 4 The role of Initiator in the Template displacement. a Location of the toehold-binding sites for both RdRP and N genes. Typical curves illustrating the fluorescence signal kinetics of the NISDA assay over time, designed for b, RdRP gene and c, N gene using different Initiators of T/DNAt-15 (solid blue circle), T/INA\textsuperscript{1–8} (hollow red circle), and T/INA\textsuperscript{1–15} (hollow green square). Water (hollow black triangle) means no Initiator, only M1 and M2. Source data for (b, c) are provided as a source data file.

(Supplementary Discussion 1 and Supplementary Fig. 6a). For the folding of the binding sites with an additional 30 nt and 60 nt upstream and downstream, the RdRP again folded stronger than N (Supplementary Discussion 1). Moreover for RdRP gene, the whole binding site was in a structured region, whereas for the N gene, the toehold part of the binding site was in a high probable unpaired region (Supplementary Fig. 6b, c). We furthermore observed that RdRP did not have alternative foldings in contrast to N (Supplementary Fig. 7). These observations prompted us to explore the joint binding and folding patterns of the reverse complement of the binding site alone and the binding sites with context. For this purpose, we employed IntaRNA\textsuperscript{31} at 42 °C on the RdRP and N gene pairs, respectively. We found that both the hybridization and the energy of the duplex indeed was lower for the N gene than the RdRP (Supplementary Fig. 8). These observations are consistent with the N probe functioning better than the RdRP probe. The obtained results demonstrate that it is very important to select a target sequence within the whole genome to be not only specific but also accessible at 42 °C. Therefore, for our further experiments, we used probes designed for N gene to perform the assay evaluation and clinical validation.

Sensitivity and selectivity of the NISDA assay. The NISDA assay was developed for the N gene and its performance was further studied. The sensitivity analysis was carried out using serial dilutions of synthetic SARS-CoV-2 RNA (TWIST Bioscience) in Nuclease-free water and spiked in known negative oropharyngeal RNA extracts (provided by clinical microbiology department, Hvidovre Hospital, Denmark). Figure 5a and b illustrates the NISDA assay response to different concentrations of SARS-CoV-2 RNA diluted in water and negative matrix, respectively. The ultrafast response of the assay is evident as the fluorescence intensity could dramatically reach to its maximum value within the first minutes of the reaction. Considering the plots of fluorescence enhancement slope as the function of RNA concentration, the semi-quantitative behavior of the assay can be comprehended. Although, sudden enhancement of the fluorescence signals resulting from rapid amplification makes it difficult to accurately define the slopes thereby calculating the LoD. As a result, in order to calculate the sensitivity of our assay, we performed a quantification study based on the endpoint fluorescence readings (tables in Fig. 5a, b). The cutoff value was defined as 95% of confidence interval (i.e., the mean value of the signals obtained from the negative samples plus two times of their standard deviation (mean ± 2 SD)\textsuperscript{32}, and the lowest concentration of the SARS-CoV-2 RNA that showed a greater signal than the cutoff value was defined as the LoD. Therefore, the LoD of NISDA assay was five and ten copies µL\textsuperscript{−1} of SARS-CoV-2 RNA diluted in water and negative matrix, respectively (one copy µL\textsuperscript{−1} corresponds to five copies per reaction). In addition, the developed NISDA assay did not show any false-negative result. Moreover, no cross-reactivity was observed for the NISDA assay (prepared for SARS-CoV-2) tested on other various respiratory viral nucleic acids of human coronaviruses 229E (H CoV 229E), influenza A virus subtype H1N1 and H3N2, Boca virus 1, H enterovirus 68, H rhinovirus 89, and Mumps (Fig. 5c, d).

Clinical validation of the NISDA assay. We performed the clinical validation of the NISDA assay using N gene of the targeted sequence for the detection of SARS-CoV-2 RNA from oropharyngeal RNA extract specimens. A total of 127 clinical samples (62 verified CoV-19 positive with diverse Ct values and 65 verified CoV-19 negative) were tested. A qualitative test was performed based on the endpoint fluorescence signal. The extracted RNA samples provided by Hvidovre Hospital were stored at 80 °C before the assay operation. The cutoff value obtained by performing the assay on all of the negative samples (Fig. 6) was 76.01 RFU which was far below the 95% of the confidence interval of the positive samples (161.1 RFU). As shown in Fig. 6a, the NISDA assay was able to successfully identify all the 65 negative samples with no false-positive rate and 60 positives out of 62 CoV-19 positive samples (3.2 % false-negative rate) in only 30 min (Supplementary Fig. 9). The false negatives might be due to the degradation of the extracted RNA samples in the laboratory, even though, a false-negative occurrence at Ct > 37 does not rise a major concern, as it is a common issue for the qRT-PCR\textsuperscript{32}. An alternative strategy would be to design different probe sets for the E gene and run the experiments.
simultaneously to avoid probable false negatives in a back-to-back supporting approach.

In addition, the reproducibility of the NISDA assay on \( N \) gene was tested by conducting three identical experiments on one validated CoV-19 positive (\( C_t = 30 \)) and one validated CoV-19-negative oropharyngeal RNA extract sample. A sound reproducibility can be interpreted from Fig. 6b. The developed NISDA assay also showed great robustness, as it could retain 99.2% and 98.9% of its initial fluorescence signals after being stored in a dark humid chamber for a month at RT and for 2 months at 4 °C, respectively. We also conducted a similar experiment on the RdRp gene, and the assay showed a very poor sensitivity of 61.2%, relatively long response time (60 min), and the recorded data points for the true positives were close to the cutoff value (Supplementary Fig. 10). This, as mentioned before, might be due to the difficulty for the Initiator to have proper access to its target sequence to successfully undergo the Template displacement (Supplementary Discussion 1).

In order to better evaluate the NISDA assay and compare its performance with qRT-PCR, we performed another clinical study at Bispebjerg Hospital, Denmark. For the temperature control (42 °C) and fluorescence readout, we used an identical BioRad Real-Time PCR System (CFX96) which was being used for daily CoV-19 tests at the Bispebjerg Hospital (CoV-19 Diagnostics Division, Department of Clinical Biochemistry). The NISDA assay was performed on 37 randomized oropharyngeal RNA extract specimens without knowing their qRT-PCR results. The NISDA assay represented 100% sensitivity and 100% specificity (Supplementary Fig. 10). This, as mentioned before, might be due to the difficulty for the Initiator to have proper access to its target sequence to successfully undergo the Template displacement (Supplementary Discussion 1).
with no false-positive or false-negative rates (Fig. 6c, d), signifying that the RNA degradation might be the issue that we encountered during the laboratory testing. Although, a relatively high value for the confidence bands (Table 1) would be attributed to the low number of population.

Comparing with qRT-PCR, it was found that NISDA assay represented 100% sensitivity and 100% specificity for the detection of SARS-CoV-2 N gene when the target was spiked in negative matrix within the detection range (Table 1). Compared with other SARS-CoV-2-detection methods, NISDA assay showed a considerably high value of diagnostic odds ratios (DORs) for the detection of SARS-CoV-2 (6.61–8.75).

In order to further investigate the advantages of our approach against qRT-PCR and similar isothermal techniques (RT-LAMP

Fig. 6 Clinical validation of NISDA assay in oropharyngeal RNA extract specimens. a Plotting the NISDA assay data points obtained in the laboratory for 127 clinical oropharyngeal RNA extracts (65 validated CoV-19 negatives and 62 validated CoV-19 positives) together with the corresponding C\textsubscript{T} values of the positive samples; blue solid circles indicate samples considered positive by NISDA and red hollow circles indicate samples considered negative by NISDA; mean value difference between the two populations was statistically significant (P<0.001; calculated based on the unpaired two-tailed t test). 

b Reproducibility test of the NISDA assay showing the fluorescence kinetics of three identical measurements on a CoV-19-positive sample (C\textsubscript{T} = 30). CI denotes for the confidence interval. Error bars represent mean ± SD.

c On-site performance of the NISDA assay at Bispebjerg Hospital using Real-Time PCR System (CFX96) for monitoring the fluorescence kinetics of 37 clinical oropharyngeal RNA extracts (31 validated CoV-19 negatives (gray solid lines under the cutoff value) and 6 validated CoV-19 positives (blue solid lines above the cutoff value)).

d Numbers of false-negative and positive rates for two clinical validations in the laboratory and the hospital (on-site). Source data are provided as a source data file.

Table 1 Characterization of NISDA assay performance in comparison with qRT-PCR.

| Clinical samples | Sensitivity [95% CI] | Specificity [95% CI] | PPA [95% CI] | NPA [95% CI] | ln(DOR) [95% CI] |
|------------------|---------------------|---------------------|--------------|--------------|-----------------|
| Lab. test        | 96.77% [89.8–99.4%] | 100% [95.1–100%]   | 100% [94.5–100%] | 97.01% [90.6–99.5%] | 8.27 [6.68–9.86] |
| On-site test     | 100% [61.7–100%]   | 100% [88.2–100%]   | 100% [61.6–100%] | 100% [86.1–100%] | 6.61 [4.26–8.66] |
| All              | 97.06% [91.8–99.4%] | 100% [96.2–100%]   | 100% [95.1–100%] | 97.96% [92.1–99.7%] | 8.75 [7.16–10.34] |

PPA, NPA, and ln(DOR) stand for positive predictive agreement, negative predictive agreement, and natural logarithm of diagnostics odds ratio, respectively.
and RPA), we performed side-by-side experiments. As discussed in Supplementary Discussion 2 and 3 and illustrated in Supplementary Figs. 11–13, compared to qRT-PCR, NISDA was more user-friendly, faster and required simpler data analysis. Moreover, NISDA was more sensitive than RPA and compared to RT-LAMP, NISDA did not rely on a specific sample preparation method and was more robust at RT. A comparison analysis is also provided in Table 2 remarking the advantages of NISDA assay against similar molecular diagnostic methods, being rapid, nonlabourious (one-pot detection), robust, and cost-effective (nonenzymatic).

In addition, we carried out a set of experiments to evaluate whether the NISDA assay is capable of performing directly on the saliva specimens. We prepared some mimic samples by spiking synthetic SARS-CoV-2 RNA (100 copies µL⁻¹) into healthy saliva. As seen in Supplementary Fig. 14 (Protocols 1 and 2), the assay showed high background signals and did not show any response when performing on spike-in samples, even on the lysed samples. That might be due to the high density of saliva matrix to either promote nonspecific bindings or hamper proper fluorescence light transmissions through the media. Therefore, we added one more step of saliva centrifugation to obtain a cell-free matrix (Supplementary Fig. 14, Protocol 3). This time the NISDA assay showed a response, however, only two of the five spike-in samples were detected positive. The observed performance demonstrates the promising potential of NISDA assay to become more convenient and faster, nonetheless, comprehensive optimization experiments are required to increase its performance.

Discussion

To control pandemics such as COVID-19 and highly expected future outbreaks, the main approach before vaccine development or disease treatment is to prevent disease transmission. Hence, it is vital for any nation—with limited or advanced resources—to have large-scale access to reliable, accurate, fast, and economical diagnostic tests to rapidly manage patients at their healthcare facilities.

All of the current genetic detection kits/devices for SARS-CoV-2 RNA or any types of long viral genomes (>100 nt) profoundly rely on using multiple enzymes to either randomly cut the whole genome or transcribe it into smaller pieces for further amplification. The nonenzymatic approach for the whole-genome detection would attract interests from different research disciplines/industrial sectors to develop various ideas and/or reduce the costs of their current products. Although the NISDA assay was more user-friendly than qRT-PCR, automation of the reading and analysis of test results and implementation of compatible systems at the emergency ward would be more desirable. This would provide a faster screening and isolation practice in order not to unnecessarily occupy the healthcare facilities and professionals. Moreover, compared to the antigen rapid tests, the requirement for RNA extraction step before the assay implementation is another shortcoming of our assay which necessitates more researches and optimizations. We anticipate that the NISDA assay can contribute efficiently to control the current COVID-19 pandemic and expected future outbreaks, aiming to reduce the burden on the healthcare systems and enable more people to receive tests, effectively. Such a fast and sensitive diagnostic method will significantly enhance the efficiency of society’s reaction to the pandemics.

Methods

Nucleic acid design and reagents. The oligonucleotides were designed and the predicted structures and ΔG calculation were carried out using mfold webserver (http://www.unafold.org/mfold/software/download-mfold.php) and OligoAnalyser (https://eu.idtdna.com/calc/analyser). The M1 and M2 hairpin structures were rationally designed using the filter criteria of: 50 mM NaCl as the ionic strength; \( T_m \geq 42 \, ^\circ C \); ΔG ≥ 9 kcal mol⁻¹ and 30% ≤GC≤ 55% (Table 3). The structured motifs of the RdRP and N gene were folded at 42°C using the RNAfold webserver (RNAfold version 2.4.18 with options -p -d2 -noLP -T 42) 20. RNA:RNA interaction between the reverse complement of the binding site corresponding to the INAt_15 probe and the RNA with the 30 nt up- and downstream context using IntaRNA 31.

| Method         | Detection step(s) | Detection time | Enzyme(s) | RNA reverse-transcription | Robustness at RT | Thermal cycling | Ref. |
|----------------|-------------------|----------------|-----------|---------------------------|------------------|-----------------|------|
| qRT-PCR        | Single            | >1 h           | O         | O                         | Low              | O               | 40   |
| RT-RPA         | Multiple          | -1 h           | O         | O                         | Low              | ×               | 12   |
| SHERLOCK       |                   |                |           |                           |                  |                 |      |
| RT-LAMP        | Single            | 30 min         | O         | O                         | Low              | ×               | 39   |
| NISDA          | Single            | 30 min         | ×         | ×                         | High             | ×               | Present work |

O used; × not used.
at 42 °C and otherwise default parameters. The oligonucleotide sequences were synthesized by Pentabase A/S, however, the Primer templates were synthesized by TAG Copenhagen A/S, to avoid possible cross-contaminations in the production line. INA1-8 and INA1-15 for both RdRP and N genes can be directly ordered from Pentabase A/S by referring to this work. Although, one can order any given INA from Pentabase A/S with desired numbers of intercalators. Primers were shipped in dry state and dissolved in nuclease-free water then diluted in TES buffer (50 mM Tris pH = 7.4, 1 mM EDTA, 50 mM NaCl). The probes M1 and M2 were formed by annealing at 95 °C for 5 min followed by a gradual cooling down to room temperature (RT) for 1 h, and restoring at 4 °C in amber tubes (if needed). Oligonucleotide sequences are listed in (Supplementary Table 1).

### PAGE analysis.
A 12% polyacrylamide gel was prepared in 1× TBME buffer (89 mM Tris-HCl, 200 mM boric acid, 5 mM MgCl2, pH 8.0), 100 µM ammonium persulfate (APS; 10%) and 12 µL TMEAD. After 20 min of gel polymerization at room temperature (RT), the PAGE analysis was carried out in 1× TBME running buffer at 110 V for 70 min. Sample volume was composed of 6 µL of the DNA samples (10 µM) mixed with 2 µL of 6× DNA loading buffer. RedSafe™ was used for the DNA staining (1 µL in 100 mL TBE; 15 min) followed by washing with deionized water and imaging (Gel Doc™ EZ System; USA).

### In vitro synthesis and purification of the Initiator.
High throughput in vitro synthesis of Initiators was carried out by hybridization of identical concentrations (200 µM) of the Template and the corresponding complementary DNA or INA strands (T/INA1-15, T/INA1-8, and T/INA1-15). The mixture was annealed at 95 °C for 5 min followed by a gradual cooling down to RT for 1 h. PAGE purification at high gel concentration (12% TBME) was used, in order to obtain more discrete bands between the short oligo fragments (Template (22 nt); INA (30 to 37 nt); Template/INA). To attain a higher purification yield, 10-cm continuous comb engaged in 1 mm spacer was used, enabling 250 µL sample loading. The corresponding band of the Initiator was excised under a short UV irradiation, following by freezing overnight at −80 °C and crush-soaking in nuclease-free water. The oligo fragments were eluted by the gel by overnight incubation at 37 °C with 700 µg/µL agatization. Using NucleoSpin Gel and PCR Clean-up, Macherey-Nagel, the resulting solution was cleaned up to remove all the gel residues. The final concentration of the Initiator was adjusted to 380 ± 7 ng µL−1 in TES buffer (pH 7.8) and stored in 4 °C.

### Melting temperature (Tm) analysis.
The melting temperature analysis of DNA1-8, DNA1-15, and DNA1-15 was conducted by recording the fluorescence signals of the different DNA duplexes using a real-time PCR machine (CFX96, BioRad). The respective oligonucleotides were hybridized with their corresponding complementary DNA strands in TES buffer (pH 7.8) by annealing at 95 °C for 5 min followed by a gradual cooling down to RT for 1 h. In total, 10 µL of hybridized duplexes (10 µM) were mixed with 10 µL PowerUP™ SYBR™ Green Master Mix and directed to measurement. The mixtures were slowly heated from 65 to 95 °C at a constant rate of 0.5 °C min−1 while the fluorescence signals were being recorded after each temperature increment.

### NISDA assay protocol.
A step-by-step protocol describing the NISDA assay protocol can be found at Protocol Exchange™. The NISDA assay master mix was a 24 µL mixture composed of probe M1 (10 µL 22 ± 2 ng µL−1), probe M2 (10 µL 85 ± 3 ng µL−1) and the Initiator (T/INA1-15) (4 µL 380 ± 7 ng µL−1), all dissolved in TES buffer (pH 7.8). The master mix was prepared in an excess amount in the amber tube and loaded into a 96-well plate suitable for either a real-time PCR machine (CFX96, BioRad) or microplate reader equipped with temperature incubation (Synergy H1 Hybrid Multi-Mode Reader, BioTek). Then 5 µL of the ice-thawed SARS-CoV-2 RNA samples extracted from patient oropharyngeal swabs were added to each well and gently mixed by pipetting. The first column (eight wells) was assigned to the control, while 5 µL of the validated CoV-19 negative samples were loaded in each well. The plates were sealed and directed to the fluorescence kinetics measurement of the FAM over time, while the reaction temperature was fixed at the optimum 42 ± 1 °C. The obtained data after 30 min was compared with the cutoff value calculated for negative controls, and the recorded values greater than the cutoff were considered positive.

### Preparation of clinical samples, clinical evaluation, and ethical approval.
For the laboratory testing, oropharyngeal swabs from CoV-19 suspected patients were collected at Clinical Microbiology Laboratory, Hvidovre Hospital, and the validation was conducted using qRT-PCR on SARS-CoV-2 N gene. Sampling was carried out using NEST Scientific 5-ml sterile screw-cap transport tube with 1.2 mL 0.85% saline solution and sterile individually wrapped swab. Total RNA was extracted from the swab samples and eluted into the final volume of 100 ± 10 µL. The RNA samples were then shipped to the Technical University of Denmark and stored in −80 °C.
For the on-site testing, random oropharyngeal swabs from CoV-19-suspected patients were collected and provided at Clinical Biochemistry Department, Bispebjerg Hospital, and the RNA extraction was carried out using BasePurifier™ (Pentabase A/S). After validation using qRT-PCR, samples were randomized and given to the study staff (at RT) to conduct NISDA assay at the hospital. The laboratory testing, healthy donor testing, and on-site testing at Bispebjerg Hospital only involved completely anonymized samples with no personal data or possible identification of individuals. The application was considered by a combined committee involving representatives from The Information Centre for Data Approvals for The Capital Region of Denmark, The Health Research Ethics Committee for The Capital Region of Denmark, jurists from Health Research & Innovation at The Regional Center for Development, and the Data Protection Office. The combined committee determined that approval from the Hospital Board was sufficient under Danish legislations. This was the case since the purpose was validation of a new method, the process used routinely collected samples that were completely anonymized, and the project did not in any way alter standard patient care regimen. Further, individual informed consent was waived by the Ethics Committee of the Capital Region of Denmark (record no. H-20057072).

### Preparation of spike-in samples.
For the spike-in saliva sample, to obtain cell-free nucleic acids, saliva sample from a healthy donor was treated with QIAGEN protease K (10:1 v/v) for 5 min and centrifuged at high speed (18,800g; RT) for 10 min following by supernatant removal. The obtained supernatant was then mixed with one volume of lysis buffer RTL (QIAGEN) and incubated for 20 min on ice. This resulted in sample denaturation and later protection of synthetic SARS-CoV-2 RNA from nucleases. Next, SARS-CoV-2 RNA (100 copies µL−1) was spiked into the mixture and kept on ice. In total, 5 µL of the mixture was then transferred to 24 µL of NISDA mix following by incubation at 42 °C for 30 min before the fluorescence measurement.

### Statistical analysis.
Data pre-processing (i.e., baseline subtractions and normalization) were performed using Origin® 2019. Standard deviations and mean values were calculated on the basis of the data from at least three identical experiments unless otherwise mentioned in the figure captions. Statistical analysis was performed using GraphPad Prism 9. The differences between groups were calculated based on the unpaired two-tailed t test and the P values < 0.05 were defined significant. The diagnostic odds ratio and the two-sided confidence intervals of ln(DOR) were calculated as reported in literature[46].

### Reporting summary.
Further information on research design is available in the Nature Research Reporting Summary linked to this article.

### Data availability.
The evaluation report for the user-friendliness of the NISDA assay together with the uncrapped gels for Fig. 2, Supplementary Figs. 2, 3, 5, and 13b are available in the FigsShare database under the accession code 15073626. Sequence alignment and mutation analysis were performed using GISAID CoVsurver (https://www.gisaid.org/epiinfo-applications/covsurver-mutations-app/). Source data are provided with this paper.

Received: 30 January 2021; Accepted: 9 August 2021; Published online: 24 August 2021
References

1. Huang, H. et al. COVID-19: a call for physical scientists and engineers. ACS Nano 14, 3747–3754 (2020).
2. Yang, T., Wang, Y.-C., Shen, C.-F. & Cheng, C.-M. Point-of-care RNA-based diagnostic device for Covid-19. Diagnostics 10, 165 (2020).
3. Chau, C. H., Strope, J. D. & Figg, W. D. COVID-19 clinical diagnostics and testing technology. Pharmacotherapy. J. Hum. Pharmacol. Drug Ther. 40, 857–868 (2020).
4. Udugama, B. et al. Diagnosing COVID-19: the disease and tools for detection. ACS Nano 14, 3882–3835 (2020).
5. Vandenberg, O., Martiny, D., Rochas, O., van Belkum, A. & Kozlakidis, Z. Considerations for diagnostic COVID-19 tests. Nat. Rev. Microbiol. 19, 171–183 (2021).
6. Yu, C. Y., Chan, K. G., Yean, C. Y. & Ang, G. Y. Nucleic acid-based diagnostic tests for the detection SARS-CoV-2: an update. Diagnostics 11, 53 (2021).
7. Peeling, R. W. et al. Serology testing in the COVID-19 pandemic response. Lancet Infect. Dis. 20, e245–e249 (2020).
8. Kim, H. Outreach of novel coronavirus (COVID-19): what is the role of radiologists? Eur. Radiol. 30, 3266–3267 (2020).
9. Corman, V. M. et al. Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR. Eur. Surveill. 25, 2000445 (2020).
10. Basu, A. et al. Performance of Abbott ID now COVID-19 rapid nucleic acid amplification test using nasopharyngeal swabs transported in viral transport media and dry nasal swabs in a New York City academic institution. J. Clin. Microbiol. 58, e01136–20 (2020).
11. Yu, L. et al. Rapid colorimetric detection of COVID-19 coronavirus using a reverse transcriptional loop-mediated isothermal amplification (RT-LAMP) diagnostic platform. Clin. Chem. 66, 975–977 (2020).
12. Patchings, M. et al. Clinical validation of a Cass1-based assay for the detection of SARS-CoV-2 RNA. Nat. Biomed. Eng. 4, 1140–1149 (2020).
13. Yousef, B., Tuberfield, A. J., Mills, A. P., Sammel, F. C. & Neumann, I. U. A DNA-fuelled molecular machine made of DNA. Nature 406, 605–608 (2000).
14. Lee, T. et al. Single functionalized pRNA/Gold nanoparticle for ultrasensitive microRNA detection using electrochemical surface-enhanced Raman spectroscopy. Adv. Sci. 7, 1902477 (2020).
15. Mohammadniaei, M. et al. Multifunctional nanobiobead hybrid material composed of Ag/β1,3-1,6-RNA three-way junction/miRNA/ratelinic acid for non-small cell lung cancer diagnosis. ACS Appl. Mater. Interfaces 11, 8779–8788 (2019).
16. Li, B. et al. Construction of dual-color probes with target-triggered signal amplification for in situ single-molecule imaging of microRNA. ACS Nano 14, 8116–8125 (2020).
17. Wang, B., Thachuk, C., Ellington, A. D., Winfree, E. & Soloveichik, D. Effective design principles for leakless strand displacement systems. Proc. Natl Acad. Sci. USA 115, E12182–E12191 (2018).
18. Xu, G. et al. Branched hybridization chain reaction—using highly dimensional DNA nanostructures for label-free, reagent-less, multiplexed molecular diagnostics. Microsyst. Nanoeng. 5, 37 (2019).
19. Yin, P., Choi, H. M. T., Calvert, C. R. & Pierce, N. A. Programming biomolecular self-assembly pathways. Nature 451, 318–322 (2008).
20. Li, B., Chen, X. & Ellington, A. D. Adapting enzyme-free DNA circuits to multiple detection methods. Nucleic Acids Res. 39, e110–e111 (2010).
21. Do, J. Y., Jeong, J. Y. & Hong, C. A. Catalytic hairpin DNA assembly-based chemiluminescent assay for the detection of short SARS-CoV-2 target cDNA. Talanta 233, 12235 (2021).
22. Sanchita, B. et al. High-sputue isothermal amplification and detection of SARS-CoV-2. mSphere 6, e00911–e00920 (2021).
23. Wu, T. H. et al. Hybridization chain reactions targeting the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). Int. J. Mol. Sci. 21, 3216 (2020).
24. Jiao, J. et al. DNA nanoscaffold-based SARS-CoV-2 detection for COVID-19 diagnosis. Biosens. Bioelectron. 167, 112479 (2020).
25. Christensen, U. B. et al. Intercalating nucleic acids: the influence of linker length and intercalator type on their duplex stabilities. Nucleosides, Nucleotides Nucleic Acids 23, 207–225 (2004).
26. Dellett, M. & Simpson, D. A. Considerations for optimization of microRNA PCR assays for molecular diagnosis. Expert Rev. Mol. Diagn. 16, 407–414 (2016).
27. Martinez, K. et al. Locked nucleic acid based beacons for surface interaction studies and biosensor development. Anal. Chem. 81, 3448–3454 (2009).
28. Briones, C. & Moreno, M. Applications of peptide nucleic acids (PNAs) and locked nucleic acids (LNAs) in biosensor development. Anal. Bioanal. Chem. 402, 3071–3089 (2012).
29. Briones, R., M. & Moreno, M. G. Methods for detection of SARS-CoV-2 RNA. Future Virol. 14, 39–49 (2019).
30. Li, B. et al. Detection of COVID-19: a review of the current literature and future perspectives. Biosens. Bioelectron. 166, 112455 (2020).
31. Jørgensen, A. S., Gupta, P., Wengel, J. & Astakhova, I. K. Detection of SARS-CoV-2 RNA via the integration of plasmonic thermocycling and fluorescence detection in a portable device. Nat. Biomed. Eng. 4, 1159–1167 (2020).
32. Dao Thi, V. L. et al. A colorimetric RT-LAMP assay and LAMP-sequencing for detecting SARS-CoV-2 RNA in clinical samples. Sci. Transl. Med. 12, eabc7075 (2020).
33. Brown, J. et al. Comparison of SARS-CoV-2 gene real-time RT-PCR targets and commercially available mastermixes. J. Virol. Methods 295, 114215 (2021).
34. Mohammadniaei, M. et al. Protocol for one-pot detection of SARS-CoV-2 RNA based on non-enzymatic, isothermal strand displacement and amplification (NSIDA) assay. Protein.Exch. https://doi.org/10.21203/rs.3.pex-r8e-v1 (2020).
35. Glas, A. S., Lijmer, J. G., Prins, M. H., Bonsel, G. J. & Bossuyt, P. M. M. The diagnostic odds ratio: a single indicator of test performance. J. Clin. Epidemiol. 56, 1129–1135 (2003).

Acknowledgements

This work is financially supported by European Institute of Innovation & Technology (EIT) Health, Project no. 20876.

Author contributions

M.M. designed and conceived the research, performed the experiments, and wrote the manuscript. M.Z. and J.A. performed experiments and statistical analysis. U.B.C. helped to optimize the assay. L.F.H.-R., G.I.G.L., T.I.B., F.E.N., and J.R. carried out clinical sample collection from patients and participated in the clinical study and assay evaluation. M.N., T.Z., and W.W. ran extra experiments and analyzed the raw data. E.B.P., A.C.R.O., and L.T.K. participated in user-friendliness evaluation of the assay. J.G. performed the RNA structure analysis. Y.S. supervised all aspects of the study and provided methodology, validation, and visualization.

Competing interests

M.M. and Y.S. have submitted a patent application that is related to this work (application number: EP202160099, aspects of manuscript covered: The method of non-enzymatic assay for viral RNA detection). Ulfr Bech Christensen (CEO of Pentabase A/S) will produce the INAI-15 (N gene) as a research product upon future requests. The remaining authors declare no competing interests.

Additional information

Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41467-021-25387-9.

Correspondence and requests for materials should be addressed to M.M. or Y.S.

Peer review information Nature Communications thanks the anonymous reviewer(s) for their contribution to the peer review of this work.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
